- Home
- CSQ vs ZLAB Comparison
CSQ vs ZLAB Comparison
Compare CSQ & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CSQ | ZLAB |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.6B |
| IPO Year | 2004 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CSQ | ZLAB |
|---|---|---|
| Price | $20.97 | $26.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $49.60 |
| AVG Volume (30 Days) | 149.9K | ★ 767.1K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 7.53% | N/A |
| EPS Growth | N/A | ★ 38.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $460,156,000.00 |
| Revenue This Year | N/A | $9.75 |
| Revenue Next Year | N/A | $26.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $16.41 | $15.96 |
| 52 Week High | $21.17 | $34.72 |
Technical Indicators
Market Signals| Indicator | CSQ | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 55.79 | 60.70 |
| Support Level | $20.49 | $16.84 |
| Resistance Level | $21.16 | $27.22 |
| Average True Range (ATR) | 0.25 | 0.90 |
| MACD | -0.03 | -0.13 |
| Stochastic Oscillator | 80.17 | 70.98 |
Price Performance
Historical ComparisonAbout CSQ Calamos Strategic Total Return
Calamos Strategic Total Return Fund is a diversified, closed-end management investment company. The fund's objective is to provide total return through a combination of capital appreciation and current income. Its investment portfolio comprises equities, convertible securities, and high-yield corporate bonds.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.